
    
      This study including two parts: (1) Part A, open-label design, 20 patients will be enrolled
      and receive 30 mg Chidamide BIW and 25 mg exemestane QD. The main object of part A is to
      evaluate the pharmacokinetic and pharmacodynamic profile of Chidamide when in combination
      with exemestane. (2) Part B, randomized and double-blinded design, 328 patients will be
      assigned randomly in a 2:1 ratio to experiment group (30 mg Chidamide BIW + 25 mg exemestane
      QD) and control group (placebo BIW + 25 mg exemestane QD), to evaluate the efficacy and
      safety of Chidamide when in combination with exemestane in patients with locally advanced or
      metastatic estrogen receptor-positive breast cancer progressing on endocrine therapy.
    
  